• Yusuke Sakurai, Masahide Fujita, Shiori Kawasaki, Takao Sanaki, Takeshi Yoshioka, Kenichi Higashino, Soichi Tofukuji, Sosuke Yoneda, Tatsuya Takahashi, Ken Koda, Toshiyuki Asaki, Minoru Hasegawa, and Yasuhide Morioka.
• Neuroscience, Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan.
• Pain. 2019 Apr 1; 160 (4): 895-907.

AbstractMost advanced knee osteoarthritis (OA) patients experience chronic pain resistant to cyclooxygenase (COX) inhibitors. However, the cells and molecules involved in this advanced OA pain remain poorly understood. In this study, we developed a rat model of advanced knee OA by modification of the monoiodoacetate-induced OA pain model and examined involvement of synovial macrophages in advanced OA pain. Cyclooxygenase inhibitors, such as celecoxib and naproxen, and a steroid were ineffective, but an opioid and anti-nerve growth factor (NGF) antibody was effective for pain management in the advanced OA model. Similar to advanced OA patients, histological analysis indicated severe bone marrow damages, synovitis, and cartilage damage and an increase of macrophages with high expression of interleukin-1β, NGF, nitric oxide synthase (NOS) 1, NOS2, and COX-2 in the knee joint of the advanced OA model. Intravenous injection of clodronate liposomes depleted synovial macrophages, which decreased the level of not only proinflammatory mediator interleukin-1β but also NGF in the knee joint, leading to pain suppression in the advanced OA model. These data suggest the involvement of synovial macrophages in advanced knee OA pain resistant to COX inhibitors by increasing proinflammatory mediators, and that drugs targeting synovial macrophages might have potent analgesic effects.

45 keywords...

hide…